Summary
Gilead Sciences, Inc. reported strong financial results for the second quarter and first half of 2010, demonstrating robust revenue growth primarily driven by its antiviral franchise, particularly Atripla and Truvada. Total revenues increased by 15% year-over-year for the quarter to $1.93 billion and 19% for the first half to $4.01 billion. Net income also saw a significant increase, reflecting improved operational efficiency and strong product demand. The company continued to invest in research and development, with key advancements in its HIV and liver disease pipelines. Gilead also announced a new $5.0 billion stock repurchase program, underscoring its commitment to returning value to shareholders and maintaining a strong financial position with substantial cash reserves.
Financial Highlights
50 data points| Revenue | $1.93B |
| Cost of Revenue | $455.52M |
| Gross Profit | $1.35B |
| SG&A Expenses | $248.01M |
| Operating Expenses | $934.60M |
| Operating Income | $992.63M |
| Interest Expense | $17.76M |
| Net Income | $712.06M |
| EPS (Basic) | $0.41 |
| EPS (Diluted) | $0.40 |
| Shares Outstanding (Basic) | 1.76B |
| Shares Outstanding (Diluted) | 1.80B |
Key Highlights
- 1Total revenues grew 15% to $1.93 billion in Q2 2010, driven by a 15% increase in product sales.
- 2Antiviral product sales, led by Atripla and Truvada, increased by 13% and 16% for the three and six months ended June 30, 2010, respectively.
- 3Net income attributable to Gilead common stockholders increased to $712.1 million for the quarter, up from $571.4 million in Q2 2009.
- 4The company initiated significant Phase 3 clinical studies for its next-generation HIV treatment regimen.
- 5Gilead announced a new $5.0 billion, three-year stock repurchase program, demonstrating confidence in future performance and commitment to shareholder returns.
- 6Cash, cash equivalents, and marketable securities increased to $4.22 billion as of June 30, 2010, providing strong liquidity.
- 7The company is actively managing potential impacts of the U.S. healthcare reform legislation, estimating a ~$200 million reduction in U.S. net product sales for 2010.